Lanadelumab (TAKHZYRO), a treatment to routinely prevent attacks in patients with HAE Type I or II who are 12 years old and up, was recently added to Nova Scotia’s drug formulary. To access this treatment, we recommend you speak with your HAE specialist or speak a representative from Takeda’s OnePath program. You can also find details in Nova Scotia’s Pharmacare News.
This is wonderful news for eligible HAE patients living in Nova Scotia. We’d like to extend a huge thank you to both Takeda Canada and the Nova Scotia government who worked hard to ensure HAE patients have access to this treatment.